Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Down 46.9% in November

Avalo Therapeutics, Inc. (NASDAQ:AVTX) was the recipient of a significant decrease in short interest in November. As of November 30th, there was short interest totalling 5,200 shares, a decrease of 46.9% from the November 15th total of 9,800 shares. Based on an average daily volume of 45,100 shares, the short-interest ratio is currently 0.1 days. Approximately 0.1% of the shares of the company are sold short.

Analysts Set New Price Targets

Separately, HC Wainwright began coverage on Avalo Therapeutics in a research report on Thursday, October 24th. They set a “neutral” rating on the stock.

Avalo Therapeutics Stock Performance

Shares of AVTX traded up $0.12 during trading hours on Friday, reaching $9.23. The company had a trading volume of 189,188 shares, compared to its average volume of 203,906. Avalo Therapeutics has a 12-month low of $3.95 and a 12-month high of $34.46. The firm has a 50 day simple moving average of $11.16 and a 200-day simple moving average of $10.81.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Ikarian Capital LLC grew its holdings in shares of Avalo Therapeutics by 1,673.0% in the 3rd quarter. Ikarian Capital LLC now owns 970,359 shares of the company’s stock worth $9,218,000 after acquiring an additional 915,629 shares during the period. RA Capital Management L.P. purchased a new position in shares of Avalo Therapeutics in the third quarter valued at $9,186,000. Logos Global Management LP acquired a new position in shares of Avalo Therapeutics during the 2nd quarter worth $6,722,000. Finally, Affinity Asset Advisors LLC raised its stake in shares of Avalo Therapeutics by 350.0% during the 2nd quarter. Affinity Asset Advisors LLC now owns 45,000 shares of the company’s stock worth $561,000 after buying an additional 35,000 shares during the last quarter. 87.06% of the stock is owned by hedge funds and other institutional investors.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.